1. Belgium Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Fagron SA

Fagron SA

23.53
EUR
-0.15
(-0.63%)
1.76BMarket Cap
Feb 11Next Earn
Fagron SA
IOB:0HNZ
(London Stock Exchange (International))

Recent

price

23.53

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
13.09
15.15
10.24
10.35
13.46
12.69
7.82
6.04
6.57
7.45
7.71
7.9
9.38
10.45
11.95
13.03
- -
Revenue per Share
0.69
0.87
1.33
-0.97
0.49
-6.01
-0.38
0.65
0.59
0.57
0.83
0.84
0.96
0.97
1.1
1.25
- -
Basic EPS, GAAP
0.71
2.22
2.06
1.91
3.06
2.18
1.25
1.17
1.02
1.07
1.29
1.08
1.5
1.18
0.95
1.71
- -
Free Cash Flow per Basic Share
0.33
0.41
0.46
0.57
0.67
0.93
- -
- -
0.1
0.12
0.08
0.18
0.2
0.25
0.29
0.36
- -
Dividend per Share
6.11
6.73
7.38
4.65
4.65
-1.95
2.09
2.53
2.87
3.36
3.5
4.4
5.55
6.35
6.88
7.53
8.11
Book Value per Share
-2.33
-4.6
-5.39
-7.52
-12.61
-13.92
-3.08
-2.27
-2.58
-2.44
-1.87
-1.24
-0.81
-0.26
-0.1
-0.26
-2.56
Tangible Book Value per Share
32
32
33
33
33
34
54
72
72
72
72
73
73
73
73
73
73
Basic Weighted Avg Shares
424
492
338
343
447
428
422
434
472
535
556
574
684
763
872
952
- -
Sales/Revenue/Turnover
8.49
9.38
15.91
19.17
21.6
18.71
16.35
17.62
16.23
16.36
16.62
15.67
14.79
14.77
15.41
15.49
- -
Operating Margin (%)
13
15
14
9
16
14
18
15
16
26
27
26
31
35
36
44
- -
Depreciation Expense
22
28
44
-32
16
-202
-21
47
42
41
60
61
70
71
81
91
- -
Net Income, GAAP
25.21
24.11
- -
14.33
38.17
- -
- -
15.93
21.07
20.32
18.56
20.1
20.17
15.87
22.34
22.17
- -
Effective Tax Rate (%)
5.3
5.72
13.01
-9.37
3.63
-47.32
-4.87
10.76
9.01
7.68
10.72
10.63
10.18
9.25
9.24
9.56
- -
Profit Margin (%)
78
-213
49
6
7
-539
6
58
12
47
22
89
147
161
168
244
216
Working Capital
215
4
301
369
552
4
290
284
266
351
284
321
380
357
376
457
618
LT Debt
208
222
245
155
157
-65
153
185
210
246
258
325
411
468
505
556
600
Total Equity
6.56
7.24
- -
9.78
8.81
- -
- -
10.06
11.04
11
11.03
10.49
10.19
10.63
11.22
11.39
- -
Return on Invested Capital (%)
7.12
7.56
- -
-3.96
4.5
- -
- -
9.98
9.96
8.54
10.87
10.52
10.56
10.07
10.86
11.06
- -
Return on Capital (%)
11.24
13.28
19.11
-16.27
10.53
- -
- -
28.11
21.9
18.3
24.04
21.26
19.2
16.25
16.69
17.29
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
12
12
18
LT Borrowings
347
412
568
LT Finance Leases
44
45
50
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
73
73
73
Market Capitalization
1,648
1,558
1,760

Working Capital

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
372
463
496
Cash, Cash Equivalents & STI
89
185
131
Accounts Receivable, Net
96
95
123
Inventories
149
159
210
Total Current Liabilities
211
219
280
Payables & Accruals
- -
- -
- -
ST Debt
12
12
18
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-19.51%
16.88%
10.07%
Free Cash Flow
9.29%
12.65%
80.39%
Net Income, GAAP
-33.89%
8.99%
12.99%
Sales/Revenue/Turnover
8.5%
11.49%
9.2%
Total Cash Common Dividend
- -
40.38%
23.55%

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
872
2025
- -
- -
952
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.1
2025
- -
- -
1.25
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.29
2025
- -
- -
0.36
2026
- -
- -
- -
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Fagron NV (FAGR.BR) is a Belgium-based pharmaceutical compounding company that develops, markets and distributes specialized healthcare products and services to hospitals, pharmacies, clinics and patients worldwide; it operates through three segments including Essentials, which supplies pharmaceutical raw materials, compounding equipment, packaging and supplies; Brands, which offers innovative semi-finished products, pharmaceutical-grade vehicles such as emulsions, creams, Pentravan transdermal bases and SyrSpend oral suspending vehicles, formulations and total concepts; and Compounding Services, which provides sterile and non-sterile ready-to-use personalized compounded medications. Founded in 1990 in Rotterdam, Netherlands, with registered offices in Nazareth, Belgium, operational headquarters in Rotterdam and activities spanning over 30 countries across Europe, North America, Latin America, Asia-Pacific, Africa and other regions, Fagron serves more than 150,000 customers with approximately 4,000 employees. Recent developments include multiple strategic acquisitions in 2025 such as CareFirst Specialty Pharmacy and UCP in North America, Injeplast and Purifarma in Brazil, Amara in Poland, Magilab in Hungary, Bella Corp in Australia, Active Pharma Supplies in the UK and Uni-Chem and SB Trade in Serbia to strengthen market positioning and compounding capabilities; execution of 10 acquisitions in 2025 overall with mid-teens million euro annual revenues at high margins; a new U.S. dollar credit facility for North American growth; expansion investments including a $29 million upgrade to Anazao's 503B facility in Las Vegas for $150 million additional capacity by 2028; and an upgraded growth strategy emphasizing global leadership in essentials, brands acceleration, sterile services expansion and non-sterile optimization presented at its 2025 Capital Markets Day.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Fagron NV (ARSUF) Q3 2026 Sales/Trading Call Transcript

  • seekingalpha.com

    Fagron NV (ARSUF) Q2 2026 Earnings Call Transcript

  • globenewswire.com

    Fagron shareholders approve all proposed resolutions at the General Meetings

  • seekingalpha.com

    Fagron NV (ARSUF) Q1 2026 Sales/Trading Call Transcript

  • globenewswire.com

    Fagron convenes Ordinary and Extraordinary General Meeting on 11 May 2026

  • globenewswire.com

    Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth

  • globenewswire.com

    Fagron increases share capital through exercise subscription rights

  • seekingalpha.com

    Fagron NV (ARSUF) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Fagron NV (ARSUF) Q3 2025 Sales Call Transcript

  • seekingalpha.com

    Fagron: Recent Capital Markets Day Confirms Upside Potential

  • seekingalpha.com

    Fagron: FDA Warning Letter Creates New Entry Opportunity

  • seekingalpha.com

    Fagron NV (ARSUF) Q2 2023 Earnings Call Transcript